Clinical Trial Update: Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating IgPro20 to prevent infections in people with multiple myeloma and hypogammaglobulinemia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogammaglobulinemia
• Multiple Myeloma

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Status: RECRUITING